Major Depression Clinical Trial
Official title:
Observational Study of the Efficacy and Tolerability of Low-dose Phytotherapy Using the Example of St John's Wort (Hypericum Perforatum)
NCT number | NCT05477472 |
Other study ID # | OS01 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | August 2005 |
Est. completion date | January 2007 |
Verified date | July 2022 |
Source | Ceres Heilmittel AG |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This observational study observes the routine use of low-dose St John's Wort herbal mother tincture in patients with major depression. It measures intensity of depression at the beginning of St Johns Wort and after 6 weeks and evaluates tolerability and compliance.
Status | Completed |
Enrollment | 55 |
Est. completion date | January 2007 |
Est. primary completion date | January 2007 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - diagnosis of mild or moderate depression according to ICD-10 or DSM-IV - new start of CERES St John's wort mother tincture Exclusion Criteria: - at the same time as St John's wort mother tincture started, other antidepressive therapy |
Country | Name | City | State |
---|---|---|---|
Switzerland | CERES Heilmittel AG | Kesswil | Thurgau |
Lead Sponsor | Collaborator |
---|---|
Ceres Heilmittel AG | University of Zurich |
Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Hamilton Depression Scale 17 | validated tool to measure depression intensity. Maximum score 51, minimum 0. Higher score means higher intensity of depressive symptoms. | Change at 6 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03062150 -
Mineralocorticoid Receptor, NMDA Receptor and Cognitive Function in Depression
|
N/A | |
Completed |
NCT04352101 -
Bupropion Versus Escitalopram on Reward Circuitry and Motivational Deficits
|
Phase 4 | |
Completed |
NCT02855918 -
Blood Biomarkers in Suicidal Behaviour
|
N/A | |
Recruiting |
NCT03039387 -
Effects of tDCS on Cognitive Control and Emotion Regulation in Depressed Patients
|
N/A | |
Recruiting |
NCT02213016 -
Effectiveness of Repetitive Transcranial Magnetic Stimulation in Depressed Patients
|
Phase 4 | |
Completed |
NCT01636791 -
CBT Versus a Return to Work Intervention for Patients With Common Mental Illness in Primary Care
|
Phase 3 | |
Completed |
NCT01683539 -
Understanding How Cognitive Remediation Works
|
N/A | |
Recruiting |
NCT02237937 -
Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene
|
Phase 4 | |
Completed |
NCT01201148 -
Open Pilot Trial of TES for Depression
|
Phase 2 | |
Completed |
NCT00953108 -
Quetiapine Prolong, Escitalopram and Hypothalamic-pituitary-adrenocortical (HPA) Axis Activity in Depressed Patients
|
Phase 3 | |
Terminated |
NCT01244711 -
Open-Label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines
|
Phase 4 | |
Completed |
NCT00806143 -
Bilateral Versus Monolateral Repetitive Transcranial Stimulation in Depression
|
Phase 4 | |
Terminated |
NCT00695552 -
The Effect of Exercise on Depressive Symptoms in Unmedicated Patients
|
N/A | |
Completed |
NCT00711737 -
Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months
|
N/A | |
Completed |
NCT00532480 -
Study of Brain Response to Emotional Pictures Using a fMRI While on Duloxetine
|
Phase 4 | |
Completed |
NCT00466323 -
The Effectiveness of FMPO in Improving the Quality of Care for Persons With Severe Mental Illness.
|
N/A | |
Completed |
NCT00482482 -
Yoga in Unipolar and Bipolar Disorders
|
N/A | |
Completed |
NCT00616759 -
The Effect on Cognition of Terminating ECT Induced Seizures With Propofol
|
N/A | |
Recruiting |
NCT00209807 -
Effect of Escitalopram vs. Reboxetine on Gastro-intestinal Sensitivity of Patients With Major Depressive Disorder
|
Phase 4 | |
Completed |
NCT00167310 -
Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation
|
Phase 2 |